{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:01:31Z","timestamp":1753891291702,"version":"3.41.2"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T00:00:00Z","timestamp":1642118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81870498"],"award-info":[{"award-number":["81870498"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>A significant proportion of anti-neutrophil cytoplasmic antibody (ANCA) associated glomerulonephritis eventually progresses to end-stage renal disease (ESRD) thus requiring long-term dialysis. There is no consensus about which dialysis modality is more recommended for those patients with associated vasculitis (AAV-ESRD). The primary objective of this study was to compare patient survival in patients with AAV-ESRD treated with hemodialysis (HD) or peritoneal dialysis (PD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This double-center retrospective cohort study included dialysis-dependent patients who were treated with HD or PD. Clinical data were collected under standard format. The Birmingham vasculitis activity score (BVAS) was used to evaluate disease activity at diagnosis and organ damage was assessed using the vasculitis damage index (VDI) at dialysis initiation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 85 patients were included: 64 with hemodialysis and 21 with peritoneal dialysis. The patients with AAV-PD were much younger than the AAV-HD patients (48 vs. 62, <jats:italic>P<\/jats:italic> &amp;lt; 0.01) and more were female (76.2 vs. 51.6%, <jats:italic>P<\/jats:italic> = 0.05). The laboratory data were almost similar. The comorbidities, VDI score, and immuno-suppressive therapy at dialysis initiation were almost no statistical difference. Patient survival rates between HD and PD at 1 year were 65.3 vs. 90% (<jats:italic>P<\/jats:italic> = 0.062), 3 year were 59.6 vs. 90% (<jats:italic>P<\/jats:italic> &amp;lt; 0.001), and 5 years were 59.6 vs. 67.5% (<jats:italic>P<\/jats:italic> = 0.569). The overall survival was no significant difference between the two groups (<jats:italic>P<\/jats:italic> = 0.086) and the dialysis modality (HD or PD) was not shown to be an independent predictor for all-cause death (hazard ratio (HR) 0.73; 95% confidence interval (CI) 0.31\u20131.7; <jats:italic>P<\/jats:italic> = 0.473). Cardio-cerebrovascular events were the main cause of death among AAV-HD patients while infection in patients with AAV-PD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These results provide real-world data that the use of either hemodialysis or peritoneal dialysis modality does not affect patient survival for patients with AAV-ESRD who need long-term dialysis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2021.775586","type":"journal-article","created":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T04:32:37Z","timestamp":1642134757000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Patient Survival Between Hemodialysis and Peritoneal Dialysis Among End-Stage Renal Disease Patients Secondary to Myeloperoxidase-ANCA-Associated Vasculitis"],"prefix":"10.3389","volume":"8","author":[{"given":"Xueqin","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua Daniel","family":"Ooi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"Eggenhuizen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wannian","family":"Nie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangcheng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Ao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40620-017-0412-z","article-title":"ANCA-associated vasculitis with renal involvement","volume":"31","author":"Binda","year":"2018","journal-title":"J Nephrol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S0272-6386(03)00025-8","article-title":"Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study","volume":"41","author":"Booth","year":"2003","journal-title":"Am J Kidney Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"621","DOI":"10.7326\/0003-4819-143-9-200511010-00005","article-title":"Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis","volume":"143","author":"Hogan","year":"2005","journal-title":"Ann Intern Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1093\/ndt\/gfw046","article-title":"End-stage renal disease in ANCA-associated vasculitis","volume":"32","author":"Moiseev","year":"2017","journal-title":"Nephrol Dial Transplant."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.2215\/CJN.01020113","article-title":"Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis","volume":"8","author":"de Joode","year":"2013","journal-title":"Clin J Am Soc Nephrol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"102495","DOI":"10.1016\/j.autrev.2020.102495","article-title":"Clinical associations of renal involvement in ANCA-associated vasculitis","volume":"19","author":"Kronbichler","year":"2020","journal-title":"Autoimmun Rev."},{"key":"B7","doi-asserted-by":"publisher","first-page":"105883","DOI":"10.1016\/j.intimp.2019.105883","article-title":"The effect of pulse methylprednisolone induction therapy in Chinese patients with dialysis-dependent MPO-ANCA associated vasculitis","volume":"76","author":"Huang","year":"2019","journal-title":"Int Immunopharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1093\/qjmed\/hcu043","article-title":"Survival of patients with ANCA-associated vasculitis on chronic dialysis: data from the French REIN registry from 2002 to 2011","volume":"107","author":"Romeu","year":"2014","journal-title":"QJM."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1093\/ndt\/gfq523","article-title":"A retrospective study on outcome of microscopic polyangiitis in chronic renal replacement therapy","volume":"26","author":"Merino","year":"2011","journal-title":"Nephrol Dial Transplant."},{"key":"B10","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.kint.2018.11.008","article-title":"Management and treatment of glomerular diseases (part 2): conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference","volume":"95","author":"Rovin","year":"2019","journal-title":"Kidney Int."},{"key":"B11","doi-asserted-by":"publisher","first-page":"625672","DOI":"10.3389\/fimmu.2021.625672","article-title":"Glomerular immune deposition in MPO-ANCA associated glomerulonephritis is associated with poor renal survival","volume":"12","author":"Lin","year":"2021","journal-title":"Front Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1053\/j.ajkd.2019.04.031","article-title":"ANCA-associated vasculitis: core curriculum 2020","volume":"75","author":"Geetha","year":"2020","journal-title":"Am J Kidney Dis."},{"key":"B13","first-page":"S5","article-title":"Clinical analysis of ANCA-associated renal vasculitis patients with chronic dialysis","volume":"32","author":"Chen","year":"2014","journal-title":"Clin Exp Rheumatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.2215\/CJN.02500314","article-title":"Comparison of mortality of ESRD patients with lupus by initial dialysis modality","volume":"9","author":"Contreras","year":"2014","journal-title":"Clin J Am Soc Nephrol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.semarthrit.2012.09.005","article-title":"Predictors for outcomes in patients with severe ANCA-associated glomerulonephritis who were dialysis-dependent at presentation: a study of 89 cases in a single Chinese center","volume":"42","author":"Li","year":"2013","journal-title":"Semin Arthritis Rheum."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.2215\/CJN.00480115","article-title":"Outcome and treatment of elderly patients with ANCA-associated vasculitis","volume":"10","author":"Weiner","year":"2015","journal-title":"Clin J Am Soc Nephrol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1191\/0961203302lu096cr","article-title":"Reactivation of systemic lupus erythematosus in a dialysis patient after tuberculous peritonitis","volume":"11","author":"Lui","year":"2002","journal-title":"Lupus."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.1093\/ndt\/gfl407","article-title":"Streptococcal PD peritonitis\u2013a 10-year review of one centre's experience","volume":"21","author":"Shukla","year":"2006","journal-title":"Nephrol Dial Transplant."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1093\/rheumatology\/kez640","article-title":"Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines","volume":"59","author":"Tieu","year":"2020","journal-title":"Rheumatology (Oxford)."},{"key":"B20","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/ki.2009.218","article-title":"The clinical course of ANCA small-vessel vasculitis on chronic dialysis","volume":"76","author":"Lionaki","year":"2009","journal-title":"Kidney Int."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.775586\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T09:49:10Z","timestamp":1642499350000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.775586\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,14]]},"references-count":20,"alternative-id":["10.3389\/fmed.2021.775586"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.775586","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2022,1,14]]},"article-number":"775586"}}